DiscoverEAU PodcastsEMUC25 special: Dr. Rescigno talks about single agent TKI in selected mRCC patients
EMUC25 special: Dr. Rescigno talks about single agent TKI in selected mRCC patients

EMUC25 special: Dr. Rescigno talks about single agent TKI in selected mRCC patients

Update: 2025-11-18
Share

Description

UROONCO RCC associate editor Assoc. Prof. Carlotta Palumbo (IT) talks with medical oncologist Dr. Pasquale Rescigno (GB) about his presentation supporting the 'yes' position in the debate at EMUC25: “Is single agent TKI (tyrosine kinase inhibitor) still an option in selected mRCC patients? 

This interview was recorded at EMUC25 in Prague. For more updates on kidney cancer, please visit our educational platform UROONCO RCC.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

EMUC25 special: Dr. Rescigno talks about single agent TKI in selected mRCC patients

EMUC25 special: Dr. Rescigno talks about single agent TKI in selected mRCC patients

European Association of Urology